Table 3 Surgical findings for the patients received radical surgery after chemotherapy (N = 176)
XELOX group (n = 111) | DOS group (n = 65) | P | |
|---|---|---|---|
Pathological response | |||
Responders | 59 (53.1) | 48 (73.8) | 0.010 |
pCR | 10 (9.0) | 8 (12.9) | 0.685 |
Median total nodes | 30 (2–75) | 34 (9–71) | |
Median positive nodes | 4 (0–62) | 2 (0–30) | |
Median time from end of treatment to surgery | 29 (16–38) | 30 (17–42) | |
Median time from surgery to discharge | 11 (6–39) | 13 (5–43) | |
Pathological T stage | |||
ypT0 | 13 (11.7) | 9 (13.8) | 0.623 |
ypT1 | 14 (12.6) | 7 (10.7) | 0.715 |
ypT2 | 13 (11.7) | 12 (18.5) | 0.215 |
ypT3 | 35 (31.5) | 26 (40.0) | 0.254 |
ypT4 | 36 (32.5) | 11 (17.0) | 0.024 |
Combined ypT0/ypT1/ypT2/ypT3 | 75 (67.5) | 54 (83.0) | 0.038 |
Pathological N stage | |||
ypN0 (no regional lymph nodes) | 35 (31.5) | 26 (40.0) | 0.329 |
ypN1 (1–2 positive lymph nodes) | 17 (15.3) | 12 (18.5) | 0.739 |
ypN2 (3–6 positive lymph nodes) | 23 (20.7) | 10 (16.1) | 0.499 |
ypN3 (> 6 positive lymph nodes) | 36 (32.5) | 17 (28.4) | 0.480 |